Bioavailability and In-vivo Transdermal Delivery of Haloperidol
Abstract
Background: Sustained blood level with effective therapeutic blood level in
psychotic patients in the range of usual therapeutic dose is favorable.
Objectives: To investigate where this sustained and effective therapeutic blood level and improve in bioavailability could be achieved by using
haloperidol/transdermal gel formulation.
Materials and Methods: In-vivo transdermal delivery of haloperidol was
studied in rabbits comparing transdermal gel formulation containing 1, 8-cineole as penetration enhancer and oral tablet. Concentrations of haloperidol in plasma were measured by reverse phase HPLC. The pharmacokinetic parameters generated from this study were evaluated
statistically using one-way analysis of variance (ANOVA).
Result: The results showed that transdermal gel formulation increased rate and extent of absorption and improve bioavailability of haloperidol. The plasma concentrations of haloperidol were declined in biexponential fashion where the area under the curves and absorption rate Cmax/AUC elimination rate constant Kel, Tmax, mean residence time (MRT), mean absorption time (MAT), and total clearance (CLtotal) were significantly different p < 0.05, but volume of distribution (Vd) did not differ significantly p >0.05.The absolute bioavailability from the oral tablet, and the transdermal formulation was 38% and 57% respectively and highly significant P < 0.01.
Conclusion: This study suggest that it is possible to achieve significant sustained therapeutic blood levels for longer time and also suggest that further human investigations of the transdermal dosage are warranted
References
2. Forsman A, Ohman R. Pharmacokinetic studies on haloperidol in man. Curr Ther Res1976; 20: 319-36.
3. Kudo S, Ishizak T. Pharmacokinetics of Haloperidol: an update. Clin Pharmacokinet 1999; 37: 435-56.
4. Aronson JK, Sear JW. Transdermal hyoscine (scopolamine) and postoperative vomiting. Anaesthesia 1986; 41: 1-3.
5. Shaw JE. Pharmacokinetic of nitroglycerin and colonidine delivered by transdermal route. American Heart Journal 1984; 108:217- 22.
6. Good WR, Powers MS, Schenkel L. Anew transdermal delivery system for oestradiol. J Controlled Release1985; 2: 89-97.
7. Latasch L, van Steenis C. Transdermal fentanyl for postoperative pain. Acta Anaethsiaol Belg 1989; 40: 113-09.
8. Hunziker N, Feldman R, Maibach H. Animal models of percutaneous penetration: Comparison between Mexican Hairless-dogs and man. Dermatological 1978; 156:79-88.
9. Wester RC, Maibach HI. In vivo animal models for percutaneous absorption: Mechanism-Methodology-Drug Delivery. U. S. A., Marcel Dekker 1985; 251.
10. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978; 6: 547-57.
11. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. 4th ed. London, Philadelphia 1991: 146.
12. Ritschel WA. Handbook of Basic Pharmacokinetics 3rd ed. Drug Intelligence publications. Inc Hamilton, IL 62341. 1986: 269
13. Schall, R, Luus H. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. Int J Clin Pharmacol Ther Toxicol 1992; 30: 153- 9.
14. Lacey LF, keene, ON. Duquesony C et al. Evaluation of different indirect measures of rates of drug absorption in comparative pharmacokinetics. J Pharm Sci1994; 83:212-5.
15. Derendorf H, Hochhaus G, Rohatagi S et al.. Pharmacokinetics of triamcinolone aceotonide after intravenous, oral and inhaled administration. J Clin Pharmacol 1995; 35:302- 5.
16. Laszlo T, Laszlo E. Without extrapolation, Cmax/AUC is an effective metric in investigations of bioequivalence. Pharm Res 1995; 12: 937–42.
17. Culter DJ. Theory of mean absorption time, an adjunct to conventional bioavailability studies. J Pharm Pharmacol 1976; 30: 476- 8.
